Analyst James Orsborne of Stifel Nicolaus assigned a Buy rating on Circassia Pharmaceuticals (NIOX – Research Report), with a price target of ...

Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

Panmure Liberum upgraded Niox Group (CSSPF) to Buy from Hold with a 69 GBp price target Stay Ahead of the Market:Discover outperforming stocks ...

Circassian activists, like many displaced populations, have been challenged by different time zones and borders, but online cooperation has helped them overcome these logistical hurdles, spearheaded ...

aFaculty of Health Sciences, University of Southampton, Southampton, UK ...